2017年9月1日 · Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, …

vimseltinib (DCC-3014), a highly selective switch-control inhibitor of CSF1R kinase Timothy M. Caldwell, Yu Mi Ahn, Gary E. Brandt, Lara E. Davis, Michael Kaufman, Keisuke Kuida, Cynthia …

2022年10月15日 · Structure Activity Relationship optimization in a novel series of dihydropyrimidone-based CSF1R kinase inhibitors led to the discovery of compound 20 (DCC …

2021年11月1日 · Vimseltinib (DCC-3014) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of …

2022年10月15日 · Starting with lead compound 3, an SAR optimization campaign led to the discovery of vimseltinib (DCC-3014; compound 20) currently undergoing clinical evaluation for …

2021年5月28日 · DCC-3014 is an inhibitor of the CSF1R kinase that decreases tumor infiltrating myeloid cells in preclinical models. We hypothesized that DCC-3014 combined with the anti …

DCC-3014 –Highly Selective CSF1R Kinase Inhibitor 3 •DCC-3014 is a highly selective, oral, investigational switch control kinase inhibitor that exhibits nanomolar potency for CSF1R with …

2024年8月16日 · The FDA has accepted and granted priority review to a new drug application (NDA) for vimseltinib (DCC-3014), a colony-stimulating factor 1 receptor (CSF1R)-directed …

This phase Ib trial studies the side effects and best dose of DCC-3014 and how well it works when given together with avelumab for the treatment of high-grade sarcoma that has spread to …

2016年7月15日 · In vivo, DCC-3014 exhibited sustained inhibition of CSF1R in the murine cFOS PK/PD model, affording 90+% inhibition at 15 mg/kg through 24 h post dose. At steady state …